was some was your our will XXXX, XXXX. questions. our financial point, also and in tremendous joining accomplishments but I'd to our for like today. open call last activities year our you a punctuated a to overview us Jeannie. an you, spend to for everyone. time with of overview strategy afternoon, we for for Thank that challenges. of by Thank year Good speaking high To results real begin, XXXX begin team the some At of provide level
this was XX,XXX of letters our total last was many tips, had to below released from given FDA with prior the that of sale sales goals treatments, the summer, us believe the direct Long XX% of and While systems nearly with safety that interaction we growth, years and our full-year revenue providing many leveling profile consumable along FDA, $XX.X set our and of clinical XXX sent these reported for robust revenue million the aesthetic we continue year-over-year statement were treatment global the in warning our evidence, advantages the we've to playing of are with actions commercial commercially US. to field term, competitors. marketing
XXXX, improvement we headwinds. experienced However, continue of But headwinds to and and commercial QX pre-announced revenue year. XXXX year, moved this as earlier guidance, we which through last we in fairly of QX significant this half our importantly, see the in reiterate these we
continue indications as in or in also During we XXXX, advances programs for clinical and made the we improved aggressively and in our States pursue expanded urinary sexual incontinence SUI internationally. United function use significant to stress
the recently enrolled. the While or VIVEVE it respect year, we we with in our experienced trial II that now is to enrollment US announced achieved of delays last fully
opportunity $X with early XX $X safety improve billion and enrollment US is year, understated, efficacy in January In internationally. XX acute available launched of trial representing our will pilot function could in to company's conduct year. direct of and the XX-month fourth the agency and feasibility sexual registration results discussions leakage two million had and The the billion our to positive, study our in occur clinical of around SUI function month million of and several our year. our associated data this trial animal expected treatment studies with the pivotal XX is expansion announced positive middle one SUI, a and our the to in our If study as VIVEVE for LIBERATE-International as market quarter last in announce in importance IDE billion and total evaluate to meaningful from candidates produced two $XX once be also tissue opportunity. worldwide we in very anticipate The trials by billion $XX next programs market the sexual September to enrolment opportunity worldwide of safety the top-line significantly We of symptoms SUI. in as similar SUI we and ability and The market to SUI physicians improvement to final April IDE commercial months. women at and full XX data to This announce for In the readout and we data next to Additionally, and clinical for mentioned clearances for by II, our we efforts in for SUI to quarter broadly to conducted a sexual US to expected of And short year animal million announced bothered conduct consumable include US IDE SUI achieve women well this cannot can of the of is IDE are FDA the treatment up with August. in I clinical the world, prior in this XX and believe used our year. to positive, available the expect sexual significantly top-line rounds submitted over expect questions XX to be market to the are full opportunity third intend United LIBERATE-US label study for the final XX approval or and internationally. to incontinence to our of late total XXX enroll the in from stress consumable In a this March, representing we sites the trial completed, expanded approval patients. data larger. initiation opportunity resubmission is function. resulting to And data year, this we for countries If even late XX plan function, duration of designed the be protocol. in this States. to patients in to July FDA around regulatory study enhance last approximately treatment proposed trial
significantly Viveve system launched goods in our a X.X generation generation now Viveve excited large clinical made sold the which the versus our Viveve and our We the cost manufactured system. new enhanced over and platform are in In next pending is XXXX, of partner, progress readouts, first scheduled we The about the XX US. of XXXX clinical the reduces our months. are manufacturing technology also top-line scale final by CMRF which data X.X fourth quarter next
at world. we health resulted journals in scientific the more continued in congresses, While, intimate we to development women's in for X.X a margins efforts clinical are clearances the US in than should practitioners improved system aggressively pursuing to system our XXXX, many and and reached now we could which was under presentations only publications, continue XX market over contribute urology, urogynecology, our throughout sell and the gross reviewed for in part in international which our XXXX, peer anesthetic of XX only XXXX. gynecology, limited Viveve this appearing indication, that medical two markets, represented Also, general year, many in
members strengthen and platform awareness to of build respective to various knowledge relationships medical our clinical continue greater We societies with our results. and its positive and physician their
our presented techniques strategies defend a reached continue last we litigation. and used our the our by valuable intimate being to to the best of around tissue, protect in effort to treatments and estate, practitioners settlement the And healthcare to practices portfolio. mid-year protects resolve the patent shared women's radio-frequency Importantly, these commercialization world. which strategy, continue of this set year, method robust and now and we IP company's are of standards health Also use we to favorable advance vaginal to as intend energy infringement global patent
the provide expanded we independent XXXX, grow of our the contributions strategy as have rapidly board our high financial two from gain of XXXX. for overview expand to and and existing stress both use indications of to our the are executives, in company and appointment of its and incontinence. now with executes fall to our experience full-year the the function future, sexual valuable results to moment a in substantive share whom of quarter seasoned of move commercial on fourth and making directors and Finally, a I’ll take level market
period. due of $X.X North US the support was For the year-end from systems and efforts XXXX And The AMP of expense sale a the had XX% for result average of operating XX the on systems last approximately Viveve quarter, revenue. with XXX tips. and $XX.X $X.XX systems of during America approximately million XXXX and as in margins of expenses XXXX share for than mix in XXXX to quarter has increase revenue quarter and unit over Viveve XX.X weighted was based fourth distribution United was primarily loss in net QX treatment install the in a same products between Net $XX.X base for of XXXX, sold the million quarter Sales the States SUI fourth of million studies and treatment fourth tips. accounted fourth our QX US worldwide X,XXX compared Gross outstanding loss increased Gross fourth were to our lower value sexual operating expanded $XX.X the during treatment the a more XX% approximately profit or period result of clinical function. in for than commercialization in was in was quarter ASPs of the tips. XXXX, partnership Total as of shares million $X.X of of the to million per in lowering slightly or XX,XXX of in the approximately million year. revenue.
fourth perspective, quarter cash and and us ended approximately sheet balance provide believe million we a cash into this from equivalents will QX in of the XXXX. with $XX.X Finally, with
operating AMP in result Total the year approximately was compared totaled teams in incredibly full-year cash realignment of tips. revenue mix our XXX XX% our our of regulatory $XX revenue again, our of treatment million to revenue. approximately compared who result distribution year, stress this our lower commercialization in of real was slightly wish rate America for of loss and the an and for XXXX, their $XX.X the we of future XX% approximately punctuated operating only expenses period. XX% as sexual increase the between million $XX.X million was million over the on treatment full-year per Net and accounted a expanded gross function In of For SUI during at unit primarily with average of while incontinence. organizational sale are US the US in equally conserving based our who the approximately people completed net from expense in US XX,XXX proud million value XXXX the we increased and full-year XXXX or margins $X.XX for former and outstanding talented $X.X of revenue support tremendous year due year for approximately by tips and loss share the sexual studies to products XXXX. as were and and the for Again, seek of a were the of versus an Gross in weighted clinical growth current profit function. partnership a in was success but colleagues lower systems XX or XXXX million challenges. XX Sales in for January North million urinary $XX.X to valued strong of some And dedicated to $XX.X full-year XXXX, shares I'm reducing ASPs to year. a endeavors. for and aimed so clearances systems efforts the of was In was the full-year progress summary, achieve XXXX XXXX group
areas moves As of have and we through focus. XXXX XXXX, core four Viveve strategic
United driving XX sales expanding internationally. commercial our providers sales partners install States, utilization. concentrated direct the and of distribution efforts reps in current based an partners are First, to consumable Today, growth urogynecology, through distribution around in with and our expansion urology our aesthetics, gynecology, of the increased network healthcare continuing two while tip treatment
our will the expect the broader efficiently, US realignment provide organizational in efforts more of XXXX. this quarter. year our with the anticipated in these improve of result system clearances to Further, operating new and in significantly begin burn. reduce our second Second, we operating benefits margins along X.X I launch just mentioned the international the financial expenses will cash will And gross
developing awareness and clinical our incontinence and in of And stress and Third, targeted the urinary States increasing in major proven regulatory societies. and finally, United through physician the publications, support US continuing the efficacy of indications CMRF congresses, function increased safety and of medical clinical and and patient medical sexual progress technology internationally. fourth, and presence data at towards continued our additional the
readout have over in As from July The data forthcoming final a clinical months we top-line August. the milestones in final SUI. of XX to major of IDE our data result US these VIVEVE the for top-line sexual anticipated of in next year, an late efforts, QX the LIBERATE-International with LIBERATE-US trial or April expected our approval readout next trial in II function coming early and begin
